Earnings summaries and quarterly performance for Beauty Health.
Executive leadership at Beauty Health.
Board of directors at Beauty Health.
Research analysts who have asked questions during Beauty Health earnings calls.
OT
Olivia Tong Cheang
Raymond James Financial, Inc.
4 questions for SKIN
Also covers: BBWI, CHD, CL +13 more
Bruce Jackson
The Benchmark Company LLC
3 questions for SKIN
Also covers: BFRI, BLTE, BSEM +8 more
Jonathan Block
Stifel Financial Corp.
3 questions for SKIN
Also covers: ALGN, COO, CUTR +11 more
OC
Oliver Chen
TD Cowen
3 questions for SKIN
Also covers: BJ, BRLT, COST +21 more
Susan Anderson
Canaccord Genuity Group
3 questions for SKIN
Also covers: BODI, CDXC, COTY +13 more
AG
Allen Gong
JPMorgan Chase & Co.
2 questions for SKIN
Also covers: ESTA, GKOS, INGN +2 more
AH
Ashley Helgans
Jefferies
2 questions for SKIN
Also covers: BBWI, COTY, ELF +9 more
KW
Korinne Wolfmeyer
Piper Sandler & Co.
2 questions for SKIN
Also covers: AIRS, BBWI, CHD +14 more
NT
Navann Ty Dietschi
BNP Paribas
2 questions for SKIN
Also covers: COO, ELAN, EOLS +6 more
Sydney Wagner
Jefferies
2 questions for SKIN
Also covers: BBWI, COTY, ELF +5 more
JF
Joe Federico
Stifel Financial Corp.
1 question for SKIN
LB
Linda Bolton-Weiser
D.A. Davidson & Co.
1 question for SKIN
Also covers: CLX, ELF, FLWS +14 more
MK
Margarate Kaczor
William Blair & Company
1 question for SKIN
NT
Navann Ty
BNP Paribas S.A.
1 question for SKIN
Also covers: COO, ELAN, EOLS +4 more
Recent press releases and 8-K filings for SKIN.
BEAUTYHEALTH announces Q3 2025 results and updates full-year guidance
SKIN
Earnings
Guidance Update
Demand Weakening
- For the third quarter of 2025, BEAUTYHEALTH reported net sales of $70.7 million, a 10.3% decrease year-over-year, primarily due to lower delivery systems and consumables net sales.
- The company's net loss for Q3 2025 was $(11.0) million, an improvement of $7.3 million year-over-year due to lower operational spend and higher gross margin, partially offset by lower net sales.
- Adjusted EBITDA for Q3 2025 increased by $0.8 million year-over-year to $8.9 million, driven by lower operational spend despite lower adjusted gross profit.
- BEAUTYHEALTH updated its full-year 2025 financial guidance, projecting net sales between $293 million and $300 million and adjusted EBITDA between $37 million and $39 million.
Nov 6, 2025, 9:30 PM
Beauty Health Company Reports Q3 2025 Results, Updates Full-Year Guidance
SKIN
Earnings
Guidance Update
Demand Weakening
- The Beauty Health Company reported Q3 2025 net sales of $70.7 million, representing a 10.3% year-over-year decrease, primarily due to a 24.6% decline in device sales to $20.8 million. Consumable sales were $49.8 million, down 2.6% year-over-year, though they would have increased modestly when excluding the impact of the China transition.
- Despite the sales decline, the company achieved a GAAP gross profit of $45.6 million, an increase of 12.3%, leading to a GAAP gross margin of 64.6% and an adjusted gross margin of 68%. Adjusted EBITDA rose to $8.9 million from $8.1 million in Q3 2024, with an adjusted EBITDA margin of 12.6%.
- For full-year 2025, Beauty Health raised the low end of its revenue guidance to between $293 million and $300 million and increased its adjusted EBITDA guidance to between $37 million and $39 million. Q4 2025 net sales are projected to be between $74.5 million and $81.5 million, with adjusted EBITDA between $6.9 million and $8.9 million.
- The company's strategic priorities include protecting and growing its HydroFacial install base, driving consumable utilization, and innovation across devices and consumables. As of September 30, 2025, total active machines in the field reached 35,409 units.
Nov 6, 2025, 9:30 PM
BeautyHealth Reports Q3 2025 Financial Results and Updates Full-Year Guidance
SKIN
Earnings
Guidance Update
Demand Weakening
- BeautyHealth reported net sales of $70.7 million and Adjusted EBITDA of $8.9 million for the third quarter ended September 30, 2025, exceeding the top end of its guidance range.
- The company's gross margin improved significantly to 64.6% in Q3 2025, compared to 51.6% in the prior year period, primarily due to lower inventory-related charges and a favorable mix shift towards consumable net sales.
- 875 delivery systems were sold in Q3 2025, a decrease from 1,118 units in Q3 2024, reflecting a challenging macroeconomic environment, while the active install base grew to 35,409.
- BeautyHealth updated its Fiscal Year 2025 guidance, projecting net sales between $293 million and $300 million and Adjusted EBITDA between $37 million and $39 million.
Nov 6, 2025, 9:10 PM
Beauty Health Company Appoints Pedro Malha as President and CEO
SKIN
CEO Change
Executive Compensation
- The Beauty Health Company has appointed Pedro Malha as its new President and Chief Executive Officer, effective October 1, 2025.
- Mr. Malha succeeds Marla Beck, who will step down as President and CEO on September 30, 2025, and will remain in an advisory role until no later than December 31, 2025.
- Mr. Malha brings over 20 years of experience in the global healthcare and medical device sectors, having most recently served as Worldwide Division President and Corporate Officer of Abbott Laboratories.
- His compensation package includes an annual base salary of $800,000, a one-time cash bonus of $450,000, and an annual cash performance bonus targeted at 125% of his base salary. He will also receive a one-time initial equity grant award of $2,556,000 and a 2025 annual equity grant award of $2,000,000.
Sep 30, 2025, 8:32 PM
Quarterly earnings call transcripts for Beauty Health.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more